Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04543773 · ClinicalTrials.gov registry record · NA

Individualized Targeting and Neuromodulation of Late-Life Depression

A NA study of Major Depressive Disorder, sponsored by University of New Mexi.

Active
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT04543773 is a NA study of Major Depressive Disorder that is active but no longer recruiting, run by University of New Mexi. The registered enrollment target is 24 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04543773, a NA study of Major Depressive Disorder, is active but no longer recruiting, sponsored by University of New Mexi.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.

Conditions Studied

Interventions

  • DEVICE rTMS

Study Locations (1)

New Mexico

  • University of New Mexico HSC - Albuquerque

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-10-01
Est. Completion 2026-07-01
Phase NA

Sponsor

University of New Mexi

76 total trials

What the Registry Record Tells You About NCT04543773

The ClinicalTrials.gov registry entry for NCT04543773 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which rTMS is the first listed.

NCT04543773 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.

Frequently Asked Questions

What is clinical trial NCT04543773 about?

NCT04543773 is a clinical study titled "Individualized Targeting and Neuromodulation of Late-Life Depression". An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.

What is the current status of trial NCT04543773?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-10-01. Estimated completion is 2026-07-01.

What conditions does trial NCT04543773 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT04543773?

The interventions under investigation include: rTMS (DEVICE).

Who is sponsoring clinical trial NCT04543773?

This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04543773 being conducted?

This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.